Hydrogenology
Hydrogenology editorial study record

Hydrogen-Rich Saline Attenuates Chronic Allodynia after Bone Fractures via Reducing Spinal CXCL1/CXCR2-Mediated Iron Accumulation in Mice

Wang Y et al. · Brain Sci. 2022;12(12):1610.

PreclinicalOther formsPublished 2022
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Preclinical

Reported design

Controlled mouse fracture experiment with dose-response and mechanistic comparisons

Research topic

Musculoskeletal and pain research

Administration classification

Other forms

Study result signal

Not reported in this record.

Outcome type

Not reported in this record.

Reported in the source

Methods at a glance

Population or model

Mice with tibial fracture and intramedullary pinning

Sample

Behavioral comparisons commonly n=6/group and biochemical comparisons n=4/group; multiple mechanistic groups

Duration

Three daily injections on days 4–6, with follow-up of developing allodynia; separate established-pain test on day 14

Intervention

Hydrogen-rich saline 1, 5 or 10 mL/kg intraperitoneally once daily on days 4–6; a separate experiment used one 10 mL/kg dose on day 14

Hydrogen form

H₂ dissolved in saline — H₂ only, not Brown’s gas and not inhalation.

H₂ specification

Dose reported as saline volume per body weight; dissolved-H₂ concentration was not extracted as a numeric value.

H₂ flow

Not applicable — injected saline, not gas inhalation.

O₂ delivered with H₂

No O₂ was co-delivered as part of the intervention.

Comparator

Fracture mice receiving saline, sham controls and additional pathway-manipulation groups

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Mechanical and cold allodynia, spinal CXCL1/CXCR2, transferrin receptor, iron and pathway experiments

Reported result

Repeated 5 and 10 mL/kg doses, but not 1 mL/kg, reduced fracture-associated allodynia. A single 10 mL/kg day-14 dose produced a transient reduction; pathway experiments were also reported.

Results-extraction completeness

Dose-response, principal results and figures checked in the open-access full text; the many mechanistic groups have not been extracted outcome by outcome.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

Preclinical fracture-pain model, small groups and multiple mechanistic experiments. The results do not establish analgesic benefit after human fractures.

Applies directly to

Mouse fracture-associated allodynia, not people with fracture pain.

Preliminary appraisal framework

Not reported in this record.

Preliminary risk-of-bias status

Not reported in this record.

Appraisal rationale

Not reported in this record.

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

PMID: 36552070 · DOI: 10.3390/brainsci12121610

Publisher access

Open-access full text is available through PMC.

Extraction basis

Open-access PMC full text and PubMed record.

Record revision

2026-08-10